Prevalence of cannabis use, disorder, and medical card possession in U.S. military veterans: Results from the 2019-2020 National Health and Resilience in Veterans Study

2021 ◽  
pp. 106963
Author(s):  
Melanie L. Hill ◽  
Mallory Loflin ◽  
Brandon Nichter ◽  
Sonya B. Norman ◽  
Robert H. Pietrzak
Keyword(s):  
National Health ◽  
Military Veterans ◽  
Cannabis Use ◽  
Cannabis Use Disorder ◽  
Medical Card

Genetic Influences in Cannabis Use Disorder and Psychosis: Dopamine and Beyond

2017 ◽  
Vol 22 (42) ◽  
pp. 6392-6396 ◽  
Author(s):  
Amine Benyamina ◽  
Laurent Karila ◽  
Geneviève Lafaye ◽  
Lisa Blecha
Keyword(s):  
Cannabis Use ◽  
Genetic Influences ◽  
Cannabis Use Disorder

scholarly journals Genetic Liability to Cannabis Use Disorder and COVID-19 Hospitalization

2021 ◽  
Author(s):  
Alexander S. Hatoum ◽  
Claire L. Morrison ◽  
Sarah M.C. Colbert ◽  
Evan A. Winiger ◽  
Emma C. Johnson ◽  
...  
Keyword(s):  
Cannabis Use ◽  
Cannabis Use Disorder ◽  
Genetic Liability

Psychosocial and pharmacological treatments for cannabis use disorder and mental health comorbidities: a narrative review

2021 ◽  
pp. 1-12
Author(s):  
Rachel Lees ◽  
Lindsey A. Hines ◽  
Deepak Cyril D'Souza ◽  
George Stothart ◽  
Marta Di Forti ◽  
...  
Keyword(s):  
Mental Health ◽  
Clinical Decision Making ◽  
Treatment Compliance ◽  
Narrative Review ◽  
Cannabis Use ◽  
Psychotic Symptoms ◽  
Motivational Enhancement Therapy ◽  
Cannabis Use Disorder ◽  
Pharmacological Treatments ◽  
Health Comorbidities

Abstract Cannabis is the most widely used illicit drug worldwide, and it is estimated that up to 30% of people who use cannabis will develop a cannabis use disorder (CUD). Demand for treatment of CUD is increasing in almost every region of the world and cannabis use is highly comorbid with mental disorders, where sustained use can reduce treatment compliance and increase risk of relapse. In this narrative review, we outline evidence for psychosocial and pharmacological treatment strategies for CUD, both alone and when comorbid with psychosis, anxiety or depression. Psychosocial treatments such as cognitive behavioural therapy, motivational enhancement therapy and contingency management are currently the most effective strategy for treating CUD but are of limited benefit when comorbid with psychosis. Pharmacological treatments targeting the endocannabinoid system have the potential to reduce cannabis withdrawal and cannabis use in CUD. Mental health comorbidities including anxiety, depression and psychosis hinder effective treatment and should be addressed in treatment provision and clinical decision making to reduce the global burden of CUDs. Antipsychotic medication may decrease cannabis use and cannabis craving as well as psychotic symptoms in patients with CUD and psychosis. Targeted treatments for anxiety and depression when comorbid with CUD are feasible.

Sign in / Sign up

Export Citation Format

Share Document